Pulmonary Bacteriophage Therapy on Pseudomonas aeruginosa Cystic Fibrosis Strains: First Steps Towards Treatment and Prevention
2011

Phage Therapy for Pseudomonas Infections in Cystic Fibrosis

Sample size: 5 publication 10 minutes Evidence: high

Author Information

Author(s): Morello Eric, Saussereau Emilie, Maura Damien, Huerre Michel, Touqui Lhousseine, Debarbieux Laurent

Primary Institution: Institut Pasteur, Paris, France

Hypothesis

Can bacteriophage therapy effectively treat lung infections caused by multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis patients?

Conclusion

Bacteriophage treatments significantly improved survival rates in mice infected with multidrug-resistant Pseudomonas aeruginosa.

Supporting Evidence

  • A single dose of bacteriophage treatment given 2 hours after infection resulted in over 95% survival.
  • A four-day preventive treatment led to 100% survival in mice.
  • Bacteriophage treatments correlated with reduced levels of pro-inflammatory markers and improved histological outcomes.

Takeaway

Scientists are using special viruses called bacteriophages to help sick mice fight off a bad germ that makes their lungs hurt, and it works really well!

Methodology

Mice were infected with a Pseudomonas aeruginosa strain and treated with bacteriophages intranasally; survival and various health markers were monitored.

Potential Biases

Potential bias in the selection of bacteriophage strains and the experimental model used.

Limitations

The study was conducted in mice, and results may not directly translate to humans.

Participant Demographics

Mice (Balb/c males, 8 weeks old) were used in the study.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1371/journal.pone.0016963

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication